Cardiff Oncology CEO Mani Mohindru Acquires 34,364 Shares and Warrants

This Form 4 filing reports that Mani Mohindru, Chief Executive Officer and Director of Cardiff Oncology, Inc., acquired 34,364 shares of common stock on July 14, 2026, at a price of $1.455 per share, bringing his total direct holdings to 59,067 shares. Simultaneously, he received 34,364 Common Stock Purchase Warrants exercisable at $1.33 per share, with the warrants becoming exercisable six months after issuance or upon approval of a stockholder vote to increase authorized shares. The warrants have a five-and-a-half-year term from the initial exercise date. The total transaction value for the stock purchase was approximately $50,000. This filing represents a significant insider purchase by the company's CEO.